VIATRIS INC. Business Acquisition, Pro Forma Earnings Per Share, Diluted
VIATRIS INC. (VTRS) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of $0.08 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2026-02-26
- VIATRIS INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2023-09-30 was $0.28, a 7.69% increase year-over-year.
- VIATRIS INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2023-06-30 was $0.22, a 0.00% change year-over-year.
- VIATRIS INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2022-09-30 was $0.26.
- VIATRIS INC. business acquisition, pro forma earnings per share, diluted for the quarter ending 2022-06-30 was $0.22.
- VIATRIS INC. business acquisition, pro forma earnings per share, diluted for fiscal 2023 was $0.08, a 94.90% decline from fiscal 2022.
- VIATRIS INC. business acquisition, pro forma earnings per share, diluted for fiscal 2022 was $1.57.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.08 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $0.28 10-Q · filed 2023-11-08 | $0.71 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.22 10-Q · filed 2023-08-07 | $0.43 10-Q · filed 2023-08-07 | ||
| 2022-12-31 | $1.57 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $0.26 10-Q · filed 2023-11-08 | $0.75 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.22 10-Q · filed 2023-08-07 | $0.49 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |